Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 24:13:1028246.
doi: 10.3389/fimmu.2022.1028246. eCollection 2022.

Short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer

Rui Song  1 , Li Liu  2 , Qingbo Pan  1 , Jin Liu  3 , Jiahe Tan  4 , Juan Deng  2 , Qin Deng  2 , Zijin Lin  2 , Min Chen  1 , Mingli Peng  1 , Hong Ren  1 , Jia Ming  2
Affiliations

Short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer

Rui Song et al. Front Immunol. .

Abstract

Background: The aim of this study was to explore the short-term safety and immunogenicity of inactivated and peptide-based SARS-CoV-2 vaccines in patients with endocrine-related cancer (ER).

Methods: Eighty-eight patients with ER cancer and 82 healthy controls who had completed a full course of inactivated or peptide-based SARS-CoV-2 vaccines were recruited. Adverse events (AEs) were recorded. Responses to receptor-binding domain IgG antibody (anti-RBD-IgG), neutralizing antibodies (NAbs) and RBD+ memory B cells (MBCs) were evaluated.

Results: Approximately 26.14% (23/88) of patients with ER cancer reported AEs within 7 days, which was comparable to that reported by healthy controls (24.39%, 20/82). Both the overall seroprevalence of anti-RBD-IgG and NAbs was obviously lower in the cancer group (70.45% vs. 86.59%, P < 0.05; 69.32% vs. 82.93%, P < 0.05, respectively). Anti-RBD-IgG and NAbs titers exhibited similar results, and dropped gradually over time. Patients with ongoing treatment had an attenuated immune response, especially in patients receiving active chemotherapy. The frequency of overall RBD+ MBCs was similar between the two groups, but the percentage of active MBCs was remarkably reduced in patients with ER cancer. Unlike antibody titers, MBCs responses were relatively constant over time.

Conclusion: Inactivated and peptide-based COVID-19 vaccines were well tolerated, but with lower immunogenicity for ER cancer patients. More intensive antibody monitoring and timely booster immunization is recommended for patients with ER cancer presenting disordered subpopulations of RBD+ MBCs.

Keywords: COVID-19; SARS-COV-2; cancer; memory B cells; vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Responses of antibodies and RBD+ B cells to the SARS-COV-2 vaccines. The responses of antibodies (A–D) in healthy controls and patients with ER cancer. Change in antibody titers over time (E, F). The correlation between anti-RBD-IgG and NAbs (G). ER, endocrine-related, RBD, receptor-binding domain, NAbs, neutralizing antibodies, MBCs, memory B cells. *p < 0.05, ***p < 0.001, ****p < 0.0001.
Figure 2
Figure 2
Responses of antibodies and RBD+ B cells to the SARS-COV-2 vaccines. The responses of antibodies (A–D) and RBD+ MBCs (E–I) in patients with ER cancer of different TNM grade. ER, endocrine-related, RBD, receptor-binding domain, NAbs, neutralizing antibodies, MBCs, memory B cells. *p < 0.05, **p < 0.01, ****p < 0.0001.
Figure 3
Figure 3
Responses of antibodies and RBD+ B cells to the SARS-COV-2 vaccines. Responses of antibodies (A–D) and RBD+ MBCs (E–I) in patients with ER cancer with/without metastasis. ER, endocrine-related, RBD, receptor-binding domain, NAbs, neutralizing antibodies, MBCs, memory B cells. *p < 0.05, **p < 0.01,***p < 0.001, ****p < 0.0001.
Figure 4
Figure 4
Responses of antibodies and RBD+ B cells to the SARS-COV-2 vaccines. Responses of antibodies (A–D) and RBD+ MBCs (E–I) in breast cancer patients of different genotype. ER, endocrine-related, RBD, receptor-binding domain, NAbs, neutralizing antibodies, MBCs, memory B cells. *p < 0.05, **p < 0.01,***p < 0.001, ****p < 0.0001.
Figure 5
Figure 5
Responses of antibodies and RBD+ B cells to the SARS-COV-2 vaccines. The responses of antibodies (A–D) and RBD+ MBCs (E–I) in patients with thyroid cancer with single/multiple tumors. ER, endocrine-related, RBD, receptor-binding domain, NAbs, neutralizing antibodies, MBCs, memory B cells. *p < 0.05, **p < 0.01.
Figure 6
Figure 6
Responses of antibodies and RBD+ B cells to the SARS-COV-2 vaccines. Responses of antibodies (A–D) and RBD+ MBCs (E–I) in patients with ER cancer of different treatment types. ER, endocrine-related, RBD, receptor-binding domain, NAbs, neutralizing antibodies, MBCs, memory B cells. *p < 0.05, **p < 0.01,***p < 0.001, ****p < 0.0001.
Figure 7
Figure 7
Responses of antibodies and RBD+ B cells to the SARS-COV-2 vaccines. The responses of antibodies (A–D) and RBD+ MBCs (E–I) in patients with breast cancer treated with/without chemotherapy. ER, endocrine-related, RBD, receptor-binding domain, NAbs, neutralizing antibodies, MBCs, memory B cells. *p < 0.05, **p < 0.01,***p < 0.001, ****p < 0.0001.
Figure 8
Figure 8
Responses of antibodies and RBD+ B cells to the SARS-COV-2 vaccines. Responses to antibodies (A–D) and RBD+ MBCs (E–I) in patients with thyroid cancer treated with/without I131 therapy. ER, endocrine-related, RBD, receptor-binding domain, NAbs, neutralizing antibodies, MBCs, memory B cells. *p < 0.05, **p < 0.01.
Figure 9
Figure 9
Responses of antibodies to the SARS-COV-2 vaccines over time. The responses of antibodies (A–D) over time. The red or blue dots represent samples recorded prior to booster vaccine, and the green or orange dots represent samples recorded after booster vaccine. ER, endocrine related, RBD, receptor-binding domain, NAbs, neutralizing antibodies.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Mohammad NS, Nazli R, Zafar H, Fatima S. Effects of lipid based multiple micronutrients supplement on the birth outcome of underweight pre-eclamptic women: A randomized clinical trial. Pak J Med Sci (2022) 38(1):219–26. doi: 10.12669/pjms.38.1.4396 - DOI - PMC - PubMed
    1. Horn L, Garassino M. Covid-19 in patients with cancer: Managing a pandemic within a pandemic. Nat Rev Clin Oncol (2021) 18(1):1–2. doi: 10.1038/s41571-020-00441-5 - DOI - PMC - PubMed
    1. Goshen-Lago T, Szwarcwort-Cohen M, Benguigui M, Almog R, Turgeman I, Zaltzman N, et al. . The potential role of immune alteration in the cancer-Covid19 equation-a prospective longitudinal study. Cancers (Basel) (2020) 12(9):2421. doi: 10.3390/cancers12092421 - DOI - PMC - PubMed
    1. Taghizadeh-Hesary F, Porouhan P, Soroosh D, Peyroshabany B, Shahidsales S, Keykhosravi B, et al. . Covid-19 in cancer and non-cancer patients. Int J Cancer Manage (2021) 14(4):e110907. doi: 10.5812/ijcm.110907 - DOI
    1. Javadinia SA, Alizadeh K, Mojadadi M-S, Nikbakht F, Dashti F, Joudi M, et al. . Covid-19 vaccination in patients with malignancy; a systematic review and meta-analysis of the efficacy and safety. Front Endocrinol (Lausanne) (2022) 13:860238. doi: 10.3389/fendo.2022.860238 - DOI - PMC - PubMed

Publication types